R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
News Protein misfolding specialist Gain nets $40m from IPO Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with prot
Events Partner Content 3rd Annual Computational Drug Development (CDD) for Biologic... CDD for Biologics | 13-15 November 2018 | Boston, USA
News Five projects share £100m UK-US Cancer Grand Challenges fund Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
